These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

116 related articles for article (PubMed ID: 31276860)

  • 61. Severe disease reactivation in four patients with relapsing-remitting multiple sclerosis after fingolimod cessation.
    Berger B; Baumgartner A; Rauer S; Mader I; Luetzen N; Farenkopf U; Stich O
    J Neuroimmunol; 2015 May; 282():118-22. PubMed ID: 25903738
    [TBL] [Abstract][Full Text] [Related]  

  • 62. Long-term results from a phase 2 extension study of fingolimod at high and approved dose in relapsing multiple sclerosis.
    Montalban X; Comi G; Antel J; O'Connor P; de Vera A; Cremer M; Sfikas N; von Rosenstiel P; Kappos L
    J Neurol; 2015 Dec; 262(12):2627-34. PubMed ID: 26338810
    [TBL] [Abstract][Full Text] [Related]  

  • 63. Primary cutaneous CD30
    Connolly A; Grandi V; Stefanato CM; Palmer R; Weir A; Whittaker S
    Br J Dermatol; 2018 Dec; 179(6):1400-1401. PubMed ID: 30007065
    [No Abstract]   [Full Text] [Related]  

  • 64. Trial of Fingolimod versus Interferon Beta-1a in Pediatric Multiple Sclerosis.
    Chitnis T; Arnold DL; Banwell B; Brück W; Ghezzi A; Giovannoni G; Greenberg B; Krupp L; Rostásy K; Tardieu M; Waubant E; Wolinsky JS; Bar-Or A; Stites T; Chen Y; Putzki N; Merschhemke M; Gärtner J;
    N Engl J Med; 2018 Sep; 379(11):1017-1027. PubMed ID: 30207920
    [TBL] [Abstract][Full Text] [Related]  

  • 65. Real-World Safety and Patient Profile of Fingolimod in Relapsing-Remitting Multiple Sclerosis: A Prospective Analysis in Buenos Aires, Argentina.
    Rojas JI; Patrucco L; Miguez J; Cristiano E
    Clin Neuropharmacol; 2017; 40(6):251-254. PubMed ID: 28976408
    [TBL] [Abstract][Full Text] [Related]  

  • 66. Acute and long-term effects of fingolimod on heart rhythm and heart rate variability in patients with multiple sclerosis.
    Akbulak RÖ; Rosenkranz SC; Schaeffer BN; Pinnschmidt HO; Willems S; Heesen C; Hoffmann BA
    Mult Scler Relat Disord; 2018 Jan; 19():44-49. PubMed ID: 29127856
    [TBL] [Abstract][Full Text] [Related]  

  • 67. Comparison of efficacy and safety of oral agents for the treatment of relapsing-remitting multiple sclerosis.
    Guarnera C; Bramanti P; Mazzon E
    Drug Des Devel Ther; 2017; 11():2193-2207. PubMed ID: 28814828
    [TBL] [Abstract][Full Text] [Related]  

  • 68. [Treatment of relapsing-remitting multiple sclerosis with fingolimod in routine clinical practice].
    Alcala-Vicente C; Perez-Miralles FC; Gascon-Gimenez F; Bosca-Blasco I; Navarre-Gimeno A; Coret-Ferrer F; Casanova-Estruch B
    Rev Neurol; 2017 May; 64(10):445-453. PubMed ID: 28497440
    [TBL] [Abstract][Full Text] [Related]  

  • 69. Critical vasospasm during fingolimod (FTY720) treatment in a patient with multiple sclerosis.
    Schwarz A; Korporal M; Hosch W; Max R; Wildemann B
    Neurology; 2010 Jun; 74(24):2022-4. PubMed ID: 20548047
    [No Abstract]   [Full Text] [Related]  

  • 70. Reduced fingolimod dosage treatment for patients with multiple sclerosis and lymphopenia or neutropenia.
    Tanaka M; Park K; Tanaka K
    Mult Scler; 2013 Aug; 19(9):1244-5. PubMed ID: 23322501
    [No Abstract]   [Full Text] [Related]  

  • 71. The participation of varicella zoster virus in relapses of multiple sclerosis.
    Sotelo J; Ordoñez G; Pineda B; Flores J
    Clin Neurol Neurosurg; 2014 Apr; 119():44-8. PubMed ID: 24635924
    [TBL] [Abstract][Full Text] [Related]  

  • 72. Analysis of cardiac monitoring and safety data in patients initiating fingolimod treatment in the home or in clinic.
    Brown B; Weiss JL; Kolodny S; Meng X; Williams IM; Osborne JA
    BMC Neurol; 2019 Nov; 19(1):287. PubMed ID: 31729968
    [TBL] [Abstract][Full Text] [Related]  

  • 73. Postoperative cystoid macular oedema in a patient on fingolimod.
    Gaskin JC; Coote M
    BMJ Case Rep; 2015 May; 2015():. PubMed ID: 25969500
    [TBL] [Abstract][Full Text] [Related]  

  • 74. The effect of oral immunomodulatory therapy on treatment uptake and persistence in multiple sclerosis.
    Warrender-Sparkes M; Spelman T; Izquierdo G; Trojano M; Lugaresi A; Grand'Maison F; Havrdova E; Horakova D; Boz C; Oreja-Guevara C; Alroughani R; Iuliano G; Duquette P; Girard M; Terzi M; Hupperts R; Grammond P; Petersen T; Fernandez-Bolaños R; Fiol M; Pucci E; Lechner-Scott J; Verheul F; Cristiano E; Van Pesch V; Petkovska-Boskova T; Moore F; Kister I; Bergamaschi R; Saladino ML; Slee M; Barnett M; Amato MP; Shaw C; Shuey N; Young C; Gray O; Kappos L; Butzkueven H; Kalincik T; Jokubaitis V;
    Mult Scler; 2016 Apr; 22(4):520-32. PubMed ID: 26199347
    [TBL] [Abstract][Full Text] [Related]  

  • 75. Outcomes of switching directly to oral fingolimod from injectable therapies: Results of the randomized, open-label, multicenter, Evaluate Patient OutComes (EPOC) study in relapsing multiple sclerosis.
    Fox E; Edwards K; Burch G; Wynn DR; LaGanke C; Crayton H; Hunter SF; Huffman C; Kim E; Pestreich L; McCague K; Barbato L;
    Mult Scler Relat Disord; 2014 Sep; 3(5):607-19. PubMed ID: 26265273
    [TBL] [Abstract][Full Text] [Related]  

  • 76. Heart rate variability decreases after 3 months of sustained treatment with fingolimod.
    Vehoff J; Haegele-Link S; Humm A; Kaegi G; Mueller SK; Sauter R; Tettenborn BE; Hundsberger T
    J Neurol; 2017 Nov; 264(11):2313-2317. PubMed ID: 28993873
    [TBL] [Abstract][Full Text] [Related]  

  • 77. Primary cutaneous Epstein-Barr virus-positive diffuse large B-cell lymphoma (DLBCL) in a patient taking fingolimod.
    Wills A; Fan G; Kim E; Okada CY; White KP; Hopkins RS
    Dermatol Online J; 2019 Sep; 25(9):. PubMed ID: 31738840
    [TBL] [Abstract][Full Text] [Related]  

  • 78. First-dose effects of fingolimod after switching from injectable therapies in the randomized, open-label, multicenter, Evaluate Patient OutComes (EPOC) study in relapsing multiple sclerosis.
    Hughes B; Cascione M; Freedman MS; Agius M; Kantor D; Gudesblatt M; Goldstick LP; Agashivala N; Schofield L; McCague K; Hashmonay R; Barbato L;
    Mult Scler Relat Disord; 2014 Sep; 3(5):620-8. PubMed ID: 26265274
    [TBL] [Abstract][Full Text] [Related]  

  • 79. Recurrence of disease activity during pregnancy after cessation of fingolimod in multiple sclerosis.
    Meinl I; Havla J; Hohlfeld R; Kümpfel T
    Mult Scler; 2018 Jun; 24(7):991-994. PubMed ID: 28920764
    [TBL] [Abstract][Full Text] [Related]  

  • 80. Relapses in patients treated with fingolimod after previous exposure to natalizumab.
    Comi G; Gold R; Dahlke F; Sinha A; von Rosenstiel P; Tomic D; Kappos L
    Mult Scler; 2015 May; 21(6):786-90. PubMed ID: 25257618
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 6.